Abstract 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) interconverts the inactive
glucocorticoid cortisone and its active form cortisol. It is widely expressed and, although …

Inhibition of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) has been
proposed as a novel therapeutic target for the treatment of type 2 diabetes mellitus. Over 170 …

Despite state-of-the-art reperfusion therapy, morbidity and mortality remain significant in
patients with an acute myocardial infarction. Therefore, novel strategies to limit myocardial …

Atherosclerosis is a chronic inflammatory disease in which initial vascular damage leads to
extensive macrophage and lymphocyte infiltration. Although acutely glucocorticoids …

The importance of the renin-angiotensin-aldosterone system (RAAS) in the development of
atherosclerotic has been experimentally documented. In fact, RAAS components have been …

The objective of this study was to perform a systematic review of published literature on
differentially expressed genes (DEGs) in human epicardial adipose tissue (EAT) to identify …

Circulating glucocorticoid (GC) levels are controlled by the Hypothalamo–Pituitary–Adrenal
(HPA) axis, but within tissues, GC availability is controlled by the isoforms of 11β (Beta) …

11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts inert glucocorticoids into
active forms, thereby increasing intracellular glucocorticoid levels, important to restrain acute …

BMS-816336 (6n-2), a hydroxy-substituted adamantyl acetamide, has been identified as a
novel, potent inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β …

Glucocorticoids have a diverse array of functions affecting almost all tissues in the body.
While circulating cortisol levels are under the control of the hypothalamo–pituitary–adrenal …